Skip to content
AnalystLens

IDEXX Laboratories Annual Report, Year Ended Dec 31, 2015

Filing Date
Filed February 17, 2016
Period End
December 31, 2015
Security
IDXX
One revenue dollarkept$0.12
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Oct ’19Oct ’19
  2. Material agreement8-K · Dec ’21Dec ’21
  3. Leadership change8-K · Mar ’26Mar ’26

Summary

Summary of the 10-K filed February 17, 2016. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories' FY2015 10-K shows a company that grew revenue 7.8% to $1.60 billiona (organic growth of 13.4%, with a 6.2% currency headwind), driven by its Companion Animal Group (CAG), which accounts for roughly 85% of sales.

Recurring diagnostic revenue, which includes VetLab consumables, rapid assay kits, and reference lab services, makes up about 72% of consolidated revenue. Operating income rose 15.2% to $299.9 millionb, though it includes an $8.2 million software impairment, and diluted EPS was $2.05, up from $1.79. The margin story is mixed: gross margin improved to 55.6%, but the company absorbed one-time costs from its shift to an all-direct U.S. sales model that took effect January 1, 2015, and it moved away from distributors that now carry competing products.

The balance sheet changed meaningfully. Management aggressively repurchased stock, buying back 5.7 million shares for $406 millionc, and funded this with debt. Total long-term debt rose to $597 million, with an additional $573 million drawn on the $850 million revolver.

Stockholders' equity turned negative at $(84) million, and working capital was negative $35 milliond. Cash and marketable securities totaled $343 million. Management expects a stronger U.S. dollar to reduce 2016 revenue by about $40 million and diluted EPS by about $0.26.

Foreign sales were 39% of revenue. Key risks for investors include the all-direct U.S. transition and loss of distributor coverage, growing competition from lateral-flow rapid tests and Heska, Zoetis, and Antech, consolidation among corporate veterinary hospital owners that may shift purchasing or steer testing to rival reference labs, currency exposure, and rising leverage that is constrained by a 3.5x debt-to-EBITDA covenant.

Key Highlights

  1. Revenue rose 7.8% to $1,601.9M (organic growth 13.4%); CAG segment revenue grew 10.9% to $1,356.3M and represents about 85% of sales
  2. Recurring CAG Diagnostics revenue of $1,146.5M (+10.3%) comprises roughly 72% of consolidated revenue, with VetLab consumables up 16.1% to $396.5M
  3. Operating income rose 15.2% to $299.9M (18.7% margin), including an $8.2M impairment on internally developed software; the adjusted margin was roughly 19.2%
  4. Diluted EPS increased to $2.05 from $1.79 (+14.5%), helped by a 6.2% reduction in weighted diluted shares to 93.6M, reflecting aggressive buybacks
  5. Share repurchases of $406M (5.7M shares) were funded in part by debt: long-term senior notes rose to $597M and the revolver balance reached $573M, pushing stockholders' equity to a deficit of $(84)M
  6. The all-direct U.S. sales transition (effective Jan 1, 2015) drove distributor margin capture but added working capital needs and accounts receivable, and it resulted in lost exclusivity with former distributors who now carry competitors' products
  7. Management guides to a 2016 headwind from a stronger dollar of about $40M in revenue, $31M in operating profit, and $0.26 in diluted EPS, partly offset by hedging gains of $8M and $0.06

Follow one dollar

Of each $1.00 of revenue in FY2015, IDEXX Laboratories kept $0.12.

  1. Revenue$1.60B100.0%
  2. Cost of revenue−$711.6M44.4%
  3. Gross profit$890.3M55.6%
  4. Operating costs−$590.4M36.9%
  5. Operating income$299.9M18.7%
  6. Interest, other & tax−$107.8M6.7%
  7. Net income$192.1M12.0%
Computed from 10-KFY2015filed February 17, 2016Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2015 revenue went

$1.60B
  • Cost of revenue: $711.6M, 44% of revenue
  • Other operating costs: $490.7M, 31% of revenue
  • Net income: $192.1M, 12% of revenue
  • R&D: $99.7M, 6.2% of revenue
  • Interest, other & tax: $107.8M, 6.7% of revenue

Kept 12% as net income

Full revenue history →

Financial Statements

FY2015 against FY2014

Line itemFY2015FY2014Change
Revenue$1.60B$1.49B+7.8%
Cost of Revenue$711.62M$669.69M+6.3%
Gross Profit$890.27M$816.12M+9.1%
R&D Expenses$99.68M$98.26M+1.4%
Operating Income$299.91M$260.25M+15.2%
Interest Expense$29.24M$15.43M+89.5%
Net Income$192.08M$181.91M+5.6%
EPS (Basic)$2.07$1.82+13.7%
EPS (Diluted)$2.05$1.79+14.5%
Shares Outstanding (Basic)92.60M100.09M−7.5%
Shares Outstanding (Diluted)93.65M101.50M−7.7%

Frequently Asked Questions

  1. Why did IDEXX's stockholders' equity turn negative in 2015?

    Equity fell from $117.6M at year-end 2014 to $(84.0)M at year-end 2015 mainly because of $412M in share repurchases and a $34M hit from other comprehensive loss (currency translation and hedging). Net income of $192M only partly offset these. The company funded buybacks with debt, and its retained earnings fell to $318M from $1,675M because the repurchases are charged against retained earnings. Negative book equity is a result of capital return policy and does not by itself indicate an operating problem, but it does mean leverage is higher.

  2. How significant is the shift to an all-direct U.S. sales model?

    It is a major strategic change. Starting January 1, 2015, IDEXX sells rapid assay kits and VetLab consumables directly in the U.S., ending exclusive distributor agreements. This captured distributor margin and lifted 2015 U.S. revenue growth, but it also brought one-time costs ($9.5M non-recurring in 2014, plus about $5M of ramp-up expense), a $25M revenue drawdown in Q4 2014, higher receivables and working capital needs, and increased competitive exposure as former distributors now carry rival products.

  3. What are the main risks to IDEXX's growth?

    The 10-K highlights several: competition from lower-priced lateral-flow rapid tests after a patent expired in early 2015, and from Antech, Zoetis, Heska, and Abaxis; consolidation among corporate veterinary owners such as Mars/Banfield and VCA, which may move testing to their own reference labs; sensitivity to pet visit volumes and economic conditions; regulatory and testing-pattern changes in livestock and dairy; and foreign currency exposure, since 39% of revenue is international. Sole-source supplier dependence, including Ortho for chemistry slides, is another concentration risk.

  4. How strong is IDEXX's cash generation and liquidity?

    Operating cash flow was $216.4M in 2015, down from $235.8M, mainly because receivables rose by $50M under the new direct U.S. model and inventory grew. Capital expenditures were $82.9M, and the 2016 capex plan is about $90M. Cash and marketable securities totaled $343M. Liquidity comes from an $850M revolver with $276M available and covenant headroom under a 3.5x leverage test. The company expects its existing resources to cover operations for at least the next twelve months.

  5. What drives IDEXX's recurring revenue model?

    IDEXX places in-clinic analyzers (VetLab) at low or no upfront cost through reagent rentals and placement programs, then earns recurring revenue from proprietary consumables, SNAP test kits, and reference lab testing. Recurring diagnostic revenue reached about 72% of consolidated sales in 2015. Consumable revenue grew 16% on higher testing volumes, a broader menu (T4, SDMA), and Catalyst analyzer upgrades from VetTest. The Catalyst One analyzer, the planned SediVue Dx launch in 2016 (about $20M revenue expected), and the Neo SaaS practice management system are expected to extend this model.